Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, ...
Ahead of Robert F. Kennedy Jr.’s confirmation hearings, experts—and RFK’s own family—expressed concerns about his ...
The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...
Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...
Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...
6d
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...
Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on REPL stock, giving a Buy rating yesterday.Invest with ...
The WVU Cancer Institute is the first provider in the state to offer a new and promising treatment for extensive-stage small ...
Atara stated that the FDA’s decision was based on an inspection of ... Ebvallo became the first allogenic T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback